HEALTH● LOW1h ago · Sep 29, 2026, 5:28 PM
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC
Seeking Alpha Tech · global
AstraZeneca has submitted a New Drug Application (NDA) for the combination of savolitinib and Tagrisso for the treatment of Non-Small Cell Lung Cancer (NSCLC). This represents a potential new therapeutic option for patients.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH18m agoFood Safety dept. officials direct stall owners to maintain hygieneThe HinduHEALTH51m agoCDC data now show two measles deaths for 2026; Pennsylvania records fourSeeking Alpha TechHEALTH1h agoNigeria among high - volume markets for new $1 HIV , syphilis , hepatitis B testing bundlepremiumtimesng.com · NigeriaHEALTH1h agoNigeria among high-volume markets for new $1 HIV, syphilis, hepatitis B testing bundlePremium Times